Six Signals From SXSW You Can’t Ignore

I’ve been advising the SXSW Health & MedTech track for over a decade. Every year, the signal-to-noise ratio gets better. This year, it got loud. 

Seven days. Dozens of sessions spanning Alzheimer’s diagnostics, GLP-1s, AI in healthcare, biohacking, oncology investment, and patient trust were available with panelists from companies like Pfizer, Eli Lilly, Merck, Deloitte, MasterClass, Johns Hopkins Medical Center and more. What emerged wasn’t a collection of separate conversations — it was a convergent rallying cry for pharma marketing and technologists. 

Here’s what we heard, and what it means for your brand. 

Social Health Is the Next Frontier Pharma Is Ignoring 

The opening keynote set the tone: social health — defined as the quality of our connections with others, from close relationships to casual community interactions — is where mental health was 10 to 15 years ago. It then came up unprompted in nearly every session that followed. Alzheimer’s. Oncology. Patient trust. AI burnout. 

This isn’t coincidence. In June 2025, the WHO Commission on Social Connection published its landmark report calling social connection the third pillar of health alongside physical and mental wellbeing. The World Health Assembly adopted its first-ever resolution on social connection the same month. VML named it a top global trend. The data point that hit hardest at SXSW: 67% of Americans never participate in clubs or community groups, and 20% see people they care about fewer than twice a year. 

For pharma marketers, the implication is real: brands that build community and connection into their engagement strategy — not just their disease awareness campaigns — are sitting on a significant white space opportunity. 

AI Is a Line Cook, Not the Chef 

Every session touched AI. Not one of them said it was ready to run the kitchen alone. 

The consensus articulated most cleanly in the Data Meets AI panel featuring leaders from Pfizer and Skytale Group: AI surfaces and prepares the data, but humans bring the context that turns data into decisions. “Surfacing data is AI. Analyzing data requires that human in the mix. Judgment will always be human.” 

That framing matters for pharma. The risk isn’t that AI takes over — it’s that organizations confuse having AI tools with having an AI strategy. The brands getting value from AI right now are the ones that have built the human processes around it first. 

Trust Is the New Reach Metric 

A reconstructive surgeon went viral last year for walking out of an operating room to fight a prior authorization. She was on the SXSW stage this week. The crowd gave her a standing ovation. 

That moment crystallized something that ran through virtually every session: the healthcare system has a trust problem, and patients and HCPs both know it. Regulatory uncertainty, insurance friction, and misinformation are eroding confidence at scale. Multiple panels pointed to the same antidote — co-creation, shared decision-making, and authentic HCP voices in the content itself. 

Brands that lead with trust aren’t just doing the right thing. They’re building a durable competitive advantage that a media budget alone cannot manufacture. 

Personalization Has Left the Building. Bio-Individualism Has Arrived. 

From GLP-1 micro-dosing to bespoke Alzheimer’s diagnostic panels to custom supplement protocols, the message at SXSW was clear: “one label fits all” is over. 

Dr. Richard Isaacson of Weill Cornell described building his own blood panels because the standard ones weren’t sufficient for his patients. GLP-1 panels debated micro-dosing as equally effective as standard dosing for many patients. The biohacking session featured a Johns Hopkins neurologist alongside Wim Hof — and both were making the same argument from different angles: the individual body is the unit of analysis, not the population. 

For omnichannel marketers, this raises an uncomfortable question: if your HCP and patient messaging treats everyone in a diagnosis the same way, are you actually doing personalized omnichannel — or just multichannel with data transfer? 

The HCP Is Healthcare’s Most Underserved Customer 

This one came up in session after session, often with visible frustration from clinicians in the room. 

HCPs are burned out, data-starved, and desperate for contextual experiences. One panelist called them “the most hungry for context of any audience in healthcare.” They’re using AI to help manage treatment plans and flag cognitive decline trends in EHR systems. They’re on social media. They’re asking sharp questions at conferences about why their data environments are still so fragmented. 

And yet most brand engagement still treats HCP outreach as a targeting exercise — the right NPI, the right channel, the right call cadence. That’s expected. The brands and agencies that will win are the ones treating holistic HCP engagement as an ongoing relationship, not a channel. 

Biohacking Is Mainstreaming — and It’s Walking Into Your Patient’s Appointment 

This was the session that felt most like a glimpse into the near future. 

Wim Hof — the man who made cold water exposure a global movement — shared a stage with Dr. Kevin Tracey of the Feinstein Institutes, whose decades of vagus nerve research led directly to the FDA’s approval in July 2025 of the SetPoint System: the first implantable vagus nerve stimulator for rheumatoid arthritis. That’s not a curiosity anymore. It’s a regulatory milestone and a category signal. 

Meanwhile, patients are already arriving at appointments having self-experimented with cold plunges, GLP-1s sourced independently, breathing protocols and supplement stacks. The market is exploding — with real concerns about drug interactions and dosing accuracy that the clinicians on stage flagged loudly. These aren’t fringe behaviors. They’re mainstream patient behaviors that brands are largely not accounting for in their messaging or their HCP education. 

The Bottom Line 

The patients and HCPs have changed. The question is whether the marketing has. 

At Spectrum Science, we’ve built the omnichannel capabilities that make the kind of engagement described above possible: connected data, human-centered strategy, personalized content at scale. These six signals from SXSW aren’t trends to watch from a distance. They’re the new rules for any brand that wants to show up with personalized approaches for patients and HCPs. 

If any of this resonates — or challenges how you’re thinking about your current strategy — we’d love to continue the conversation from SXSW with you.